Jazz Pharmaceuticals (JAZZ) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $210.23, -1.95% vs the prior close of $214.42.
- Volume 636.69K shares, 0.7x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
JAZZ dips 2.0% to $210.23. Closed at $210.23, -1.95% vs the prior close of $214.42. Day range $208.18–$214.77, opened at $214.25.
JAZZ daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — JAZZ dips 2.0% to $210.23
- Closed at $210.23, -1.95% vs the prior close of $214.42. Day range $208.18–$214.77, opened at $214.25.
- Volume was 636.69K shares, 0.7x its 50-day average of 900.59K.
- Price is -12.4% vs its 50-day average ($239.94) and -2.0% vs its 200-day average ($214.47).
- 52-week range $128.80–$266.38; today's close sits at 59% of that range, 21.1% below the 52-week high.
Oct 15, 2026 — JAZZ rises 2.3% to $214.42
- Closed at $214.42, +2.28% vs the prior close of $209.65. Day range $212.19–$217.57, opened at $212.19.
- Volume was 886.40K shares, 1.0x its 50-day average of 897.17K.
- Price is -11.0% vs its 50-day average ($240.86) and +0.1% vs its 200-day average ($214.27).
- 52-week range $128.80–$266.38; today's close sits at 62% of that range, 19.5% below the 52-week high.
Oct 14, 2026 — JAZZ dips 0.4% to $209.65, a 3-month low, 7 down days in a row
- Closed at $209.65, -0.35% vs the prior close of $210.39. Day range $209.36–$215.66, opened at $210.34.
- Volume was 891.30K shares, 1.0x its 50-day average of 917.25K.
- Price is -13.3% vs its 50-day average ($241.81) and -2.1% vs its 200-day average ($214.05).
- 52-week range $128.80–$266.38; today's close sits at 59% of that range, 21.3% below the 52-week high.
- That makes 7 straight losses.
Oct 13, 2026 — JAZZ dips 2.9% to $210.39, a 3-month low, 6 down days in a row
- Closed at $210.39, -2.93% vs the prior close of $216.75. Day range $209.34–$216.86, opened at $216.86.
- Volume was 812.60K shares, 0.9x its 50-day average of 930.86K.
- Price is -13.4% vs its 50-day average ($242.85) and -1.6% vs its 200-day average ($213.86).
- 52-week range $128.80–$266.38; today's close sits at 59% of that range, 21.0% below the 52-week high.
- That makes 6 straight losses.
Oct 12, 2026 — JAZZ dips 0.8% to $216.75, a 3-month low, 5 down days in a row
- Closed at $216.75, -0.76% vs the prior close of $218.42. Day range $216.57–$221.99, opened at $218.90.
- Volume was 739.60K shares, 0.8x its 50-day average of 927.53K.
- Price is -11.0% vs its 50-day average ($243.67) and +1.4% vs its 200-day average ($213.66).
- 52-week range $128.80–$266.38; today's close sits at 64% of that range, 18.6% below the 52-week high.
- That makes 5 straight losses.
Oct 9, 2026 — JAZZ dips 1.8% to $218.42, a 3-month low, 4 down days in a row
- Closed at $218.42, -1.81% vs the prior close of $222.45. Day range $213.20–$227.00, opened at $221.79.
- Volume was 1.29M shares, 1.4x its 50-day average of 916.34K.
- Price is -10.6% vs its 50-day average ($244.39) and +2.3% vs its 200-day average ($213.42).
- 52-week range $128.80–$266.38; today's close sits at 65% of that range, 18.0% below the 52-week high.
- That makes 4 straight losses.
- SEC filings that day: 8-K.
Oct 8, 2026 — JAZZ slides 3.8% to $222.45, a 3-month low, 3 down days in a row
- Closed at $222.45, -3.78% vs the prior close of $231.19. Day range $214.68–$229.33, opened at $228.55.
- Volume was 1.27M shares, 1.4x its 50-day average of 903.42K.
- Price is -9.3% vs its 50-day average ($245.19) and +4.3% vs its 200-day average ($213.18).
- 52-week range $128.80–$266.38; today's close sits at 68% of that range, 16.5% below the 52-week high.
- That makes 3 straight losses.
Oct 7, 2026 — JAZZ ends flat (-0.1%) to $231.19, a 3-month low
- Closed at $231.19, -0.09% vs the prior close of $231.39. Day range $227.00–$235.54, opened at $229.62.
- Volume was 578.90K shares, 0.6x its 50-day average of 910.74K.
- Price is -6.0% vs its 50-day average ($245.86) and +8.6% vs its 200-day average ($212.90).
- 52-week range $128.80–$266.38; today's close sits at 74% of that range, 13.2% below the 52-week high.
Oct 6, 2026 — JAZZ dips 2.0% to $231.39, a 3-month low
- Closed at $231.39, -1.97% vs the prior close of $236.04. Day range $228.70–$236.40, opened at $236.40.
- Volume was 862.20K shares, 0.9x its 50-day average of 908.94K.
- Price is -6.1% vs its 50-day average ($246.38) and +8.9% vs its 200-day average ($212.58).
- 52-week range $128.80–$266.38; today's close sits at 75% of that range, 13.1% below the 52-week high.
Oct 5, 2026 — JAZZ ends flat (+0.2%) to $236.04, 3 up days in a row
- Closed at $236.04, +0.16% vs the prior close of $235.67. Day range $234.12–$238.87, opened at $235.51.
- Volume was 844.60K shares, 0.9x its 50-day average of 902.81K.
- Price is -4.4% vs its 50-day average ($246.86) and +11.2% vs its 200-day average ($212.24).
- 52-week range $128.80–$266.38; today's close sits at 78% of that range, 11.4% below the 52-week high.
- That makes 3 straight gains.
Oct 2, 2026 — JAZZ rises 1.1% to $235.67
- Closed at $235.67, +1.14% vs the prior close of $233.01. Day range $231.70–$237.77, opened at $233.40.
- Volume was 636.60K shares, 0.7x its 50-day average of 900.64K.
- Price is -4.7% vs its 50-day average ($247.21) and +11.2% vs its 200-day average ($211.91).
- 52-week range $128.80–$266.38; today's close sits at 78% of that range, 11.5% below the 52-week high.
JAZZ latest news & SEC filings
Every SEC filing by or about JAZZ in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 9, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Oct 8, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Oct 7, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Gala Renee D sold 2,000 shares at $236.40 (≈$472.80K) on Oct 6, 2026; now holds 141,394
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 6, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Oct 5, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Cozadd Bruce C sold 6,000 shares at $230.33 (≈$1.38M) on Oct 1, 2026; now holds 345,875
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 1, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 23, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 2.03 — Took on a new material debt or financial obligation.
Sep 15, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Sep 14, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Patil Neena M sold 1,200 shares at $240.94 (≈$289.13K) on Sep 10, 2026
- Patil Neena M sold 1,200 shares at $240.94 (≈$289.13K) on Sep 10, 2026
- Patil Neena M sold 1,200 shares at $240.94 (≈$289.13K) on Sep 10, 2026
- Patil Neena M sold 1,200 shares at $240.94 (≈$289.13K) on Sep 10, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 31, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 2.03 — Took on a new material debt or financial obligation.
- Item 3.02 — Sold unregistered shares.
- Item 8.01 — Reported other events the company considers important.
Aug 25, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Aug 10, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
Aug 10, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Aug 6, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 3, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $1.21B (prior year $1.05B) (+15.5% vs Jun 30, 2025)
- Net income: $192.80M (prior year -$718.50M) (swung to profit vs Jun 30, 2025)
- Diluted EPS: $2.78 (prior year -$11.74) (swung to profit vs Jun 30, 2025)
Things to know before you trade JAZZ
- Last results release: Aug 3, 2026 (8-K Item 2.02). Previous ones: May 5, 2026, Feb 24, 2026, Jan 12, 2026. Based on that rhythm, the next report is likely around Nov 2, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.26% (largest 3.8%).
- Liquidity: about 810.40K shares (≈$170.37M) trade per day on average.
- 52-week position: $210.23 vs a range of $128.80–$266.38 (59% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Neena M Patil sold 1,200 shares on Sep 10, 2026.
- Latest filings: 8-K Oct 9, 2026; 8-K Sep 23, 2026; 8-K Sep 15, 2026.
- Share count: 64.91M shares outstanding (Jul 27, 2026), +7.0% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
JAZZ market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 214.25 | 214.77 | 208.18 | 210.23 | 636.69K |
| Oct 15, 2026 | 212.19 | 217.57 | 212.19 | 214.42 | 886.40K |
| Oct 14, 2026 | 210.34 | 215.66 | 209.36 | 209.65 | 891.30K |
| Oct 13, 2026 | 216.86 | 216.86 | 209.34 | 210.39 | 812.60K |
| Oct 12, 2026 | 218.90 | 221.99 | 216.57 | 216.75 | 739.60K |
| Oct 9, 2026 | 221.79 | 227.00 | 213.20 | 218.42 | 1.29M |
| Oct 8, 2026 | 228.55 | 229.33 | 214.68 | 222.45 | 1.27M |
| Oct 7, 2026 | 229.62 | 235.54 | 227.00 | 231.19 | 578.90K |
| Oct 6, 2026 | 236.40 | 236.40 | 228.70 | 231.39 | 862.20K |
| Oct 5, 2026 | 235.51 | 238.87 | 234.12 | 236.04 | 844.60K |
| Oct 2, 2026 | 233.40 | 237.77 | 231.70 | 235.67 | 636.60K |
| Oct 1, 2026 | 230.33 | 234.47 | 229.85 | 233.01 | 740.60K |
| Sep 30, 2026 | 231.60 | 236.00 | 230.39 | 231.52 | 1.00M |
| Sep 29, 2026 | 236.30 | 238.00 | 229.16 | 232.35 | 777.20K |
| Sep 28, 2026 | 235.67 | 238.83 | 234.63 | 238.28 | 788.30K |
| Sep 25, 2026 | 239.12 | 239.12 | 235.66 | 237.95 | 1.13M |
| Sep 24, 2026 | 235.82 | 236.52 | 232.00 | 236.28 | 551.30K |
| Sep 23, 2026 | 239.26 | 241.33 | 231.59 | 234.88 | 792.20K |
| Sep 22, 2026 | 242.01 | 243.21 | 239.78 | 240.57 | 482.00K |
| Sep 21, 2026 | 240.87 | 244.49 | 238.53 | 241.46 | 499.20K |
About Jazz Pharmaceuticals
Jazz Pharmaceuticals (JAZZ) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in DUBLIN. State of incorporation: Ireland. Fiscal year ends December 31. SEC CIK 1232524.
JAZZ board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Bruce C Cozadd | Director | Sep 2, 2026 |
| Jennifer E. Cook | Director | Sep 2, 2026 |
| Patrick G Enright | Director | Sep 2, 2026 |
| Laura Hamill | Director | Sep 2, 2026 |
| Patrick Kennedy | Director | Sep 2, 2026 |
| Ted W Love | Director | Sep 2, 2026 |
| Heather Ann Mcsharry | Director | Sep 2, 2026 |
| Seamus Mulligan | Director | Aug 7, 2026 |
| Kenneth W O'Keefe | Director | Dec 4, 2025 |
| Norbert G Riedel | Director | Sep 2, 2026 |
| Mark Douglas Smith | Director | Sep 2, 2026 |
| Rick E Winningham | Director | Sep 2, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Patricia Carr | SVP, Chief Accounting Officer | Mar 9, 2026 |
| Renee D Gala | President & CEO | Sep 10, 2026 |
| Mary Elizabeth Henderson | SVP, Technical Operations | Sep 10, 2026 |
| Robert Iannone | EVP, Global Head of R&D & CMO | Aug 31, 2026 |
| Philip L Johnson | EVP & Chief Financial Officer | Jul 2, 2026 |
| Neena M Patil | EVP & Chief Legal Officer | Sep 14, 2026 |
| Samantha Pearce | EVP, Chief Commercial Officer | Aug 7, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 10, 2026 | Neena M Patil | Sale | 1,200 | $240.94 |
| Sep 10, 2026 | Neena M Patil | Sale | 1,200 | $240.94 |
| Sep 10, 2026 | Neena M Patil | Sale | 1,200 | $240.94 |
| Sep 10, 2026 | Neena M Patil | Sale | 1,200 | $240.94 |
| Sep 8, 2026 | Renee D Gala | Sale | 2,000 | $243.03 |
| Sep 8, 2026 | Renee D Gala | Sale | 2,000 | $243.03 |
| Sep 8, 2026 | Renee D Gala | Sale | 2,000 | $243.03 |
| Sep 8, 2026 | Renee D Gala | Sale | 2,000 | $243.03 |
| Sep 1, 2026 | Bruce C Cozadd | Sale | 6,000 | $250.13 |
| Sep 1, 2026 | Bruce C Cozadd | Sale | 6,000 | $250.13 |
| Sep 1, 2026 | Bruce C Cozadd | Sale | 6,000 | $250.13 |
| Sep 1, 2026 | Bruce C Cozadd | Sale | 6,000 | $250.13 |
| Aug 27, 2026 | Robert Iannone | Sale | 18,187 | $247.86 |
| Aug 27, 2026 | Robert Iannone | Sale | 11,423 | $248.67 |
| Aug 27, 2026 | Robert Iannone | Sale | 18,113 | $250.02 |
JAZZ financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $4.27B | $-356.15M | -5.84 | $1.36B |
| Dec 31, 2024 | $4.07B | $560.12M | 8.65 | $1.40B |
| Dec 31, 2023 | $3.83B | $414.83M | 6.10 | $1.09B |
| Dec 31, 2022 | $3.66B | $-224.06M | -3.58 | $1.27B |
| Dec 31, 2021 | $3.09B | $-329.67M | -5.52 | $778.51M |
Latest balance sheet: total assets $11.08B, total liabilities $—, cash $1.62B (as of Jun 30, 2026).
JAZZ earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 3, 2026 | 8-K Item 2.02 (results) | $251.58 |
| May 5, 2026 | 8-K Item 2.02 (results) | $212.26 |
| Feb 24, 2026 | 8-K Item 2.02 (results) | $173.83 |
| Jan 12, 2026 | 8-K Item 2.02 (results) | $163.68 |
| Nov 5, 2025 | 8-K Item 2.02 (results) | $137.22 |
| Aug 5, 2025 | 8-K Item 2.02 (results) | $113.20 |
| May 6, 2025 | 8-K Item 2.02 (results) | $111.17 |
| Feb 25, 2025 | 8-K Item 2.02 (results) | $139.67 |
| Jan 13, 2025 | 8-K Item 2.02 (results) | $123.16 |
| Nov 6, 2024 | 8-K Item 2.02 (results) | $111.55 |
| Jul 31, 2024 | 8-K Item 2.02 (results) | — |
| May 1, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on JAZZ
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.